Transdermal Delivery of Vaccines and Therapeutic Proteins - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Transdermal Delivery of Vaccines and Therapeutic Proteins
The author reviews advances in technology that may soon allow transdermal delivery of two of the fastest growing drug classes on the pharmaceutical market. This article is part of a special Drug Delivery issue.

Pharmaceutical Technology
pp. s14-s20


1. E. N. Marieb and K. Hoehn, Human Anatomy & Physiology, (Benjamin Cummings, San Francisco, CA, 8th ed., 2010).

2. J. Nicolas and B. Guy, Expert Reviews Vaccine 7 (8), 1201–1214 (2008).

3. I. M. Braverman, JID Symposium Proceedings 5 (1), 3–9 (2000).

4. A. Laurent et al., Vaccine 25, 6423–6430 (2007).

5. M. Skobe and M. Detmar, JID Symposium Proceedings 5 (1), 14–19 (2000).

6. P. S. Mortimer et al., Jrnl. of Invest. Derm. 95 (6), 677–682 (1990).

7. D. Lubach, W. Ludemann, and D. Berens Von Rautenfeld, Br. J. Dermatol. 135 (5), 733–737 (1996).

8. J. Hickling and R. Jones, WHO PATH, 1–17 (Aug. 27, 2009).

9. G. Rozis et al., Immunology 124, 329–338 (2008).

10. L. Tuft, E.M. Yagle, and S. Rogers, Laboratories of the Graduate Hospital, University of Pennsylvania and the Research Institute of Cutaneous Medicine, pp. 99–110 (Apr. 20, 1931)

11. R. T. Kenney et al., The New Engl. Jrnl. of Med. 351 (22), 2295–2301 (2004).

12. K. J. Hansen and M. A, Tomai, "Highly Efficient Transdermal Delivery of Vaccines," presented at Modern Vaccine Adjuvants and Delivery Systems, Vienna, Austria, 2009.

13 S. K. Garg et al., Diabetes Technol. & Therapeut. 11, S5–S16, (2009)

14. S.A. Shoyele, and A. Slowey, Intern. Jrnl. of Pharmaceut. 314, 1–8, (2006)

15. K. Alitalo, T. Tammela, and T. V. Petrova, Nature 438 (15), 946–953 (2005).

16. M. S. Pepper and M. Skobe, Jrnl. of Cell Biol. 163 (2), 209–213 (2003).

17. W. N. Charman, V. J. Stella, Lymphatic Transport of Drugs, (CRS Press Inc, Boca Raton, FL, 1992)

18. L. V. Leak, Jrnl. of Cell Biol. 50, 300–323 (1971).

19. L.V. Leak and J. F. Burke, Am. J. Anat. 118, 785–810 (1966).

20. C. J. H. Porter and S. A. Charman, Jrnl. of Pharmaceut. Sci. 89 (3), 297–310 (2000).

21. A. Supersaxo et al., Pharm. Res. 5 (8), 472–476 (1988).

22. W. Morozowich et al., Proceed. Intern. Symp. Control. Rep. Bioact. Mater. 17, 185–186 (1990).

23. S. Mutanishi, T. Fujita, M. Mruakami, and A. Yamamoto, Jrnl. of Contr. Rel. 46, 157–164 (1997).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here